Vaccine Administration. (1) Vaccines must be administered as directed in the most current, signed version of OHA’s Model Standing Orders for Immunizations.
Vaccine Administration. Pharmacists, as authorized pursuant to a collaborative practice agreement, may administer vaccines.
Vaccine Administration. During an influenza pandemic, it is possible that persons of all ages will need multiple doses of pandemic vaccine separated by recommended time intervals in order to mount an appropriate level of immune response to be protected from pandemic virus infection. It may also be possible that adjuvant would be required in each pandemic vaccine dose, with the need to be mixed at the point of administration to patient. Furthermore, it may be possible that only certain types or brands of adjuvant will be approved for use with certain types or brands of pandemic vaccine antigen. Also, many patients will likely receive their first and second pandemic vaccine dose from different providers at different locations. These complexities will make the need for complete and accurate vaccine administration documentation extremely important for patient safety, so that all pandemic vaccine providers are able to access this documentation to correctly assess and therefore correctly match pandemic vaccines and adjuvants between doses in each patient.
Vaccine Administration. During a pandemic, it is possible that persons of all ages will need multiple doses of pandemic vaccine separated by recommended time intervals in order to acquire an appropriate level of immune response to be protected from pandemic virus infection. Also, many patients will likely receive their first and second pandemic vaccine dose from different providers at different locations. These complexities will make the need for complete and accurate vaccine administration documentation extremely important for patient safety, so that all pandemic vaccine providers are able to access this documentation to correctly determine the need for vaccination.
Vaccine Administration i. Annually in accordance with a schedule determined by Oregon Health Authority in consultation with LPHA or as requested by Oregon Health Authority, LPHA shall submit a duly executed Immunization Program Public Provider Agreement and Public Provider Profile, both of which are requirements of CDC for any LPHA that receives State-Supplied Vaccine/IG. LPHA shall comply with the terms and conditions of the Public Provider Agreement. Oregon Health Authority will maintain and have available for review the signed Immunization Program Public Provider Agreement and Public Provider Profile at the Oregon Health Authority’s office located at 000 XX Xxxxxx Xx, Xxx 000, Xxxxxxxx, XX 00000.
Vaccine Administration. Provided to applicants and employees identified by their job title, or California Code of Regulations Title 8, Section 5193, or communicable disease exposure notification. Vaccinations may be provided by EHS or the County’s contracted provider.
Vaccine Administration. Briefly, Ab derivative is added to aluminum adjuvant which is approved for human use, to a concentration of 1 mg/ml. Young and old lemurs (n=5-6 per group) receive a subcutaneous injection of 100 µl of the mixture or adjuvant alone followed by a second injection two weeks later and then monthly thereafter. The young animals will periodically go through long intervals (up to 6 months) without vaccination to determine the reversibility of the immune response which has important safety implications. The same issue will be assessed once in the old primates. Treatment groups: 1) K6Ab1-30, which in mice elicits a strong IgG response [3;4]; 2) K6Ab1-30[E18E19], which in mice results primarily in an IgM response [5]; 3) Ab1-30[E18E19], which is not very immunogenic in mice [5], and; 4) Ab1-42 and 5) Adjuvant alone as controls. The young animals (<2 years old) will not have developed any AD pathology [2]. Many of the old mouse lemurs (>7 years old), should contain their characteristic brain pathology [2]. Antibody response, peripheral Ab levels: Animals will be Confidential Treatment has been requested for portions of this document marked with asterisks. Principal Investigator: Sxxxxxxxxx, Xxxxx, M. bled prior to vaccination, one week following the second immunization, and subsequently every other month, one week following injection. Antibody titers to the antigen and Ab will be determined by serial dilutions of plasma using an ELISA assay as described previously [3]. Measurements of Ab levels in plasma will be performed with Ab1-40/42 kits from Biosource. T-cell response: Which assay to use for this measurement remains to be determined. Behavioral testing: The primates will be assessed daily/weekly for signs of any toxicity, including evaluation of their physical appearance, measurable clinical signs, unprovoked behavior and response to external stimuli. Also, the animals will be weighed periodically. Cognitive testing is also being performed in the old lemur primates by the three-panel runway task ([6;-7]). Animals will be tested before and after immunization in a longitudinal follow-up. Those behavioral studies are performed in the laboratories of Drs. Jxxx-Xxxxxx Xxxxxxx and Nxxxxx Xxxxxx-Xxxxxxx. Brain analysis: The old primates will be killed in the summer of 2006 for analysis of brain pathology. This will include measurements of Ab levels, and stereological assessment of amyloid plaques, microhemorrhages and albumin/IgG infiltration, tau pathology, microglia...
Vaccine Administration. (1) LPHACHS must administer vaccines as directed in the most current, signed version of OHA’s Model Standing Orders for Immunizations. CHS’ Medical Director will adopt and sign model standing orders published by XXX.
Vaccine Administration. This Supervision Agreement (“Agreement”) is entered into on the effective date of , 2021 between MD/DO (“Supervising Physician”) [the physicians whose signatures appear below, each of which shall be referred to herein as “Supervising Physician”], and , N.D. (“ND”), in order to allow the ND to administer the COVID-19 Vaccination.
